PDE4A and myeloid sarcoma: We show that pharmacological inhibition of the cAMP-hydrolysing enzyme phosphodiesterase-4 (Pde4) stimulates OPC differentiation in the presence of myelin inhibitory factors likely to be present in early-stage MS lesions.